Hunan Hansen Pharmaceutical Co., Ltd.

002412

CNE100000PK2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
6.03 ^CNY	+0.50%		-1.47%	-11.06%

04-26	Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 40 million in funding from Hunan Hansen Pharmaceutical Co., Ltd.

November 10, 2022

Hansen Health Industry (Hunan) Co., Ltd. announced that it will raise CNY 40,000,000 on November 11, 2022. The transaction will include participation from returning investor, Hunan Hansen Pharmaceutical Co., Ltd. The registered capital of the company will increase from CNY 200,000,000 to CNY 240,000,000.

Latest news about Hunan Hansen Pharmaceutical Co., Ltd.

Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Hansen Pharmaceutical Gets Nod to Amend Information for Isoniazid Tablets	11-09	MT
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023	14/06/23	CI
Hunan Hansen Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022	24/05/23	CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces Board Appointments	24/05/23	CI
Hansen Pharma's Iohexol Injection Passes Drug Regulator's Evaluation	09/05/23	MT
Hunan Hansen Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	04/05/23	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23	CI
Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 40 million in funding from Hunan Hansen Pharmaceutical Co., Ltd.	10/11/22	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/04/22	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	27/04/22	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/10/21	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/08/21	CI
Hunan Hansen Pharmaceutical Co., Ltd. Approves Cash Dividend for 2020	29/04/21	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/04/21	CI
Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 138 million in funding from Hunan Hansen Pharmaceutical Co., Ltd.	13/01/21	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	26/10/20	CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20/08/20	CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan for 2019, Payable on 24 June 2020	18/06/20	CI

Chart Hunan Hansen Pharmaceutical Co., Ltd.

Duration

Period

Chart Hunan Hansen Pharmaceutical Co., Ltd.

More charts

Company Profile

Hunan Hansen Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of traditional Chinese medicine preparations, chemical medicine and medical preparations. The Companyâs main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The Company mainly distributes its products in domestic markets.

Sector

Pharmaceuticals

Calendar

21/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUNAN HANSEN PHARMACEUTICAL CO., LTD.	-11.06%	418M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B